2008 | A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R-2 MRI | 성주명 | Meeting Abstract |
2010 | A Multi-Center, Open Label Study Evaluating the Efficacy, of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R-2 mri | 성주명 | Meeting Abstract |
2015 | A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome | 문영철 | Article |
2009 | Efficacy of ICT with Deferasirox in Transfusional Iron Overloaded Patients with MDS or AA | 성주명 | Meeting Abstract |
2008 | Final Report of "Korean Multicenter AML-2000 Trial": Intention to Treat Analysis Based on Cytogenctics Risk | 문영철 | Meeting Abstract |
2011 | Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study | 성주명 | Meeting Abstract |
2015 | Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia | 문영철 | Article |
2012 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Chemotherapy Followed by High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. | 문영철 | Meeting Abstract |
2011 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis | 문영철 | Meeting Abstract |